OR WAIT null SECS
Agreement Focuses on Development of Clinical Specimen Repositories, Laboratory Services, and Research.
MRIGlobal and the University of Maryland School of Medicine today announced an intention to collaborate in the development of clinical specimen repositories, laboratory services for clinical trials, and research opportunities. The work will be performed under the collaboration agreement by MRIGlobal Dx, a division of MRIGlobal.
The non-exclusive memo of understanding has an initial two-year term, with annual renewals ongoing. Other terms of the agreement were not released.
With the agreement, the University of Maryland School of Medicine and MRIGlobal Dx plan to explore opportunities for procurement of clinical samples and patient specimen collection and banking.
Researchers in molecular and translational medicine use specimen repositories to develop new ways to diagnose, prevent, or treat diseases. Specimens may include fluids, tissues, tumors, cells and genetic material.
"This is a powerful agreement between two organizations committed to excellence and advancing knowledge," said Thomas M. Sack, Ph.D., President and Chief Executive Officer of MRIGlobal. "We are delighted to collaborate with the University of Maryland School of Medicine in bringing new diagnostic products and therapeutics to market."
University of Maryland School of Medicine Dean E. Albert Reece, who is Vice President for Medical Affairs at the University of Maryland and the John Z. and Akiko Bowers Distinguished Professor at the School of Medicine, commented: "As we continue to develop our resources as a top biomedical research institution, this agreement provides a critical service for our laboratories and clinical trials.
"We are excited to partner with a leading firm like MRIGlobal in this endeavor," he said.
For more information, visit www.mriglobaldx.com